164 related articles for article (PubMed ID: 37982205)
1. Immunotherapy rechallenge of advanced lung adenocarcinoma with cadonilimab (PD-1/CTLA-4 Bi-specific antibody): a case report.
Wang X; Yang K; Yang Y; Wang X; Yuan K
Anticancer Drugs; 2024 Mar; 35(3):288-291. PubMed ID: 37982205
[TBL] [Abstract][Full Text] [Related]
2. Patients with positive HER-2 amplification advanced gastroesophageal junction cancer achieved complete response with combined chemotherapy of AK104/cadonilimab (PD-1/CTLA-4 bispecific): A case report.
Peng J; Zhu Q; Peng Z; Chen Z; Liu Y; Liu B
Front Immunol; 2022; 13():1049518. PubMed ID: 36569905
[TBL] [Abstract][Full Text] [Related]
3. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
4. A Single-Arm Multi-Center Phase II Clinical Trial of Cadonilimab (anti-PD-1/CTLA-4) in Combination with or without Conventional Second-Line Treatment for Patients with Extensive Stage Small Cell Lung Cancer.
Chen C; Chen M; Bai Y; Li Y; Peng J; Yao B; Feng J; Zhou JG; Ma H
Technol Cancer Res Treat; 2024; 23():15330338241249690. PubMed ID: 38706247
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study).
Zhao Y; Ma Y; Fan Y; Zhou J; Yang N; Yu Q; Zhuang W; Song W; Wang ZM; Li B; Xia Y; Zhao H; Zhang L
Lung Cancer; 2023 Oct; 184():107355. PubMed ID: 37677918
[TBL] [Abstract][Full Text] [Related]
6. Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity.
Pang X; Huang Z; Zhong T; Zhang P; Wang ZM; Xia M; Li B
MAbs; 2023; 15(1):2180794. PubMed ID: 36872527
[TBL] [Abstract][Full Text] [Related]
7. Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial.
Gao X; Xu N; Li Z; Shen L; Ji K; Zheng Z; Liu D; Lou H; Bai L; Liu T; Li Y; Li Y; Fan Q; Feng M; Zhong H; Huang Y; Lou G; Wang J; Lin X; Chen Y; An R; Li C; Zhou Q; Huang X; Guo Z; Wang S; Li G; Fei J; Zhu L; Zhu H; Li X; Li F; Liao S; Min Q; Tang L; Shan F; Gong J; Gao Y; Zhou J; Lu Z; Li X; Li J; Ren H; Liu X; Yang H; Li W; Song W; Wang ZM; Li B; Xia M; Wu X; Ji J
Lancet Oncol; 2023 Oct; 24(10):1134-1146. PubMed ID: 37797632
[TBL] [Abstract][Full Text] [Related]
8. A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors.
Frentzas S; Gan HK; Cosman R; Coward J; Tran B; Millward M; Zhou Y; Wang W; Xia D; Wang ZM; Li B; Xia M; Desai J
Cell Rep Med; 2023 Nov; 4(11):101242. PubMed ID: 37852261
[TBL] [Abstract][Full Text] [Related]
9. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
10. Good response of cadonilimab (PD-1/CTLA-4 Bi-specific antibody) to patients with advanced lung adenocarcinoma after immunotherapy resistance: A case report.
An E; Lu J; Chen L
Asian J Surg; 2024 Apr; ():. PubMed ID: 38609824
[No Abstract] [Full Text] [Related]
11. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
Hayashi H; Nakagawa K
Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
[TBL] [Abstract][Full Text] [Related]
12. Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy.
Wong SK; Beckermann KE; Johnson DB; Das S
Expert Opin Biol Ther; 2021 Dec; 21(12):1623-1634. PubMed ID: 33890832
[No Abstract] [Full Text] [Related]
13. Immune checkpoint inhibitors for nonsmall cell lung cancer treatment.
Chen YM
J Chin Med Assoc; 2017 Jan; 80(1):7-14. PubMed ID: 27693088
[TBL] [Abstract][Full Text] [Related]
14. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
[TBL] [Abstract][Full Text] [Related]
15. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
16. Infusion-Related Reactions Induced by Cadonilimab (PD-1/CTLA-4 Bispecific Antibody): Seven Case Reports.
Liang W; Guo Z; Zhang Y; Yang N; Guo C; Liu T; Huang H; Chen Z
Case Rep Oncol; 2024; 17(1):361-369. PubMed ID: 38415271
[TBL] [Abstract][Full Text] [Related]
17. Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer.
Lin G; Wang Z; Chu Q; Hu Y; Huang D; Wang J; Yang F; Zhong W; Zhou C; Zhu B; Ai X; Cao B; Cao Y; Chen M; Chen X; Chu T; Duan J; Fan Y; Fang Y; Feng S; Feng W; Guo H; Han C; He Y; Hong S; Hu J; Huang M; Huang Y; Jiang D; Jiang K; Jiang R; Jin B; Jin S; Li J; Li M; Li Z; Li C; Lin J; Liu A; Liu SM; Yutao L; Liu Z; Liu Z; Liu Z; Liu Z; Liu Z; Lu Y; Lv T; Ma Z; Miao Q; Peng M; Pu X; Ren XB; Shan J; Shan J; Shen P; Shen B; Shi M; Song Y; Song Z; Su C; Sun J; Tian P; Wang J; Wang F; Wang H; Wang J; Wang Q; Wang W; Wang Y; Wu L; Wu F; Xia Y; Xie C; Xie C; Xin T; Xiong J; Xu H; Xu S; Xu Y; Xu B; Xu C; Yan X; Yang Z; Yao W; Yu Y; Feng Y; Yu Z; Yu Y; Yue D; Zhang H; Zhang H; Zhang L; Zhang L; Zhang Q; Zhang T; Zhang B; Zhao J; Zhao M; Zheng X; Zhong Q; Zhou J; Zhou P; Zhu Z; Zou J; Zou Z
Thorac Cancer; 2024 Feb; 15(5):419-426. PubMed ID: 38219795
[TBL] [Abstract][Full Text] [Related]
18. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.
Wu Z; Man S; Sun R; Li Z; Wu Y; Zuo D
Int Immunopharmacol; 2020 Aug; 85():106613. PubMed ID: 32450531
[TBL] [Abstract][Full Text] [Related]
19. Cadonilimab: First Approval.
Keam SJ
Drugs; 2022 Aug; 82(12):1333-1339. PubMed ID: 35986837
[TBL] [Abstract][Full Text] [Related]
20. [Not Available].
Mignard X; Chaabane N; Fallet V; Wislez M
Bull Cancer; 2018 Dec; 105 Suppl 1():S16-S23. PubMed ID: 30595194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
